INSYS and Aptar launch under-the-tongue delivery for cancer pain drug
INSYS Therapeutics is touting the U.S. launch of SUBSYS, an under-the-tongue fentanyl spray for cancer pain flare-ups, using a custom-made drug delivery device from Aptar Pharma ($ATR).
The drug is designed to complement the opioids cancer patients already take for background pain. SUBSYS focuses on what's called breakthrough pain--a momentary shock of severe agony--and Aptar's unit-dose delivery of fentanyl provides the ideal way to bring fast-acting relief, INSYS said in a release.
Fentanyl is already available in nasal sprays, tablets and oral transmucosal forms, but Aptar's ready-to-use spray technology doesn't require priming, unlike multi-dose spray pumps, and delivers the drug to a broad sublingual area for a quick effect, according to Aptar.
"With the early onset of action, greater bioavailability and broadest range of approved strengths, SUBSYS is poised to match the onset and intensity of a breakthrough cancer pain episode," Dr. Jeffrey Gudin of New Jersey's Englewood Hospital and Medical Center said in a statement.
Aptar figures the mucosal systemic drug delivery market to be worth more than $2 billion, and it expects the market to keep growing as drug developers favor the platform to treat migraines, insomnia and other ailments. (Image courtesy of Aptar Pharma)
FDA issues new guidelines for transmucosal delivery of pain drug
Archimedes wins FDA approval for cancer pain spray
EC investigates J&J, Novartis over generic Fentanyl delay
Meda revs REMS for opioid